The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Discovery of (2,4-Dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl]methanone (AT13387), a Novel Inhibitor of the Molecular Chaperone Hsp90 by Fragment Based Drug Design
Abstract
Inhibitors of the molecular chaperone heat shock protein 90 (Hsp90) are currently generating significant interest in clinical development as potential treatments for cancer. In a preceding publication (DOI: 10.1021/jm100059d ) we describe Astex's approach to screening fragments against Hsp90 and the subsequent optimization of two hits into leads with inhibitory activities in the low nanomolar range. This paper describes the structure guided optimization of the 2,4-dihydroxybenzamide lead molecule 1 and details some of the drug discovery strategies employed in the identification of AT13387 (35), which has progressed through preclinical development and is currently being tested in man.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Coot : model-building tools for molecular graphics
Emsley, P., & Cowtan, K. (2004) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444904019158 · Cited by 30,571
Refinement of Macromolecular Structures by the Maximum-Likelihood Method
Murshudov, G. N., Vagin, A. A., & Dodson, E. J. (1997) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444996012255 · Cited by 14,742
HSP90 and the chaperoning of cancer
Whitesell, L., & Lindquist, S. L. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1716 · Cited by 2,502
Sanguinetti, M. C., Jiang, C., Curran, M. E., & Keating, M. T. (1995) · Cell · doi:10.1016/0092-8674(95)90340-2 · Cited by 2,423
Molecular Chaperones and Protein Quality Control
Bukau, B., Weissman, J., & Horwich, A. (2006) · Cell · doi:10.1016/j.cell.2006.04.014 · Cited by 1,557
Foye's Principles of Medicinal Chemistry
Foye, W. O., Lemke, T., & Williams, D. A. (2012) · Cited by 1,407
A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors
Kamal, A., Thao, L., Sensintaffar, J., Zhang, L., Boehm, M. F., Fritz, L. C., & Burrows, F. J. (2003) · Nature · doi:10.1038/nature01913 · Cited by 1,387
Stebbins, C. E., Russo, A. A., Schneider, C., Rosen, N., Hartl, F. U., & Pavletich, N. P. (1997) · Cell · doi:10.1016/s0092-8674(00)80203-2 · Cited by 1,364
Prodromou, C., Roe, S. M., O'Brien, R., Ladbury, J. E., Piper, P. W., & Pearl, L. H. (1997) · Cell · doi:10.1016/s0092-8674(00)80314-1 · Cited by 1,265
HERG, a Human Inward Rectifier in the Voltage-Gated Potassium Channel Family
Trudeau, M. C., Warmke, J. W., Ganetzky, B., & Robertson, G. A. (1995) · Science · doi:10.1126/science.7604285 · Cited by 1,239
Structure and mechanism of the Hsp90 molecular chaperone machinery
Pearl, L. H., & Prodromou, C. (2006) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.75.103004.142738 · Cited by 1,103
Molecular and Cellular Mechanisms of Cardiac Arrhythmias
Keating, M. T., & Sanguinetti, M. C. (2001) · Cell · doi:10.1016/s0092-8674(01)00243-4 · Cited by 1,001
PDBsum: summaries and analyses of PDB structures
Laskowski, R. A. (2001) · Nucleic Acids Research · doi:10.1093/nar/29.1.221 · Cited by 849
The rise of fragment-based drug discovery
Murray, C. W., & Rees, D. C. (2009) · Nature Chemistry · doi:10.1038/nchem.217 · Cited by 791
Self-citationOn the Value of c: Can Low Affinity Systems Be Studied by Isothermal Titration Calorimetry?
Turnbull, W. B., & Daranas, A. H. (2003) · Journal of the American Chemical Society · doi:10.1021/ja036166s · Cited by 725
In Vivo Function of Hsp90 Is Dependent on ATP Binding and ATP Hydrolysis
Obermann, W. M. J., Sondermann, H., Russo, A. A., Pavletich, N. P., & Hartl, F. U. (1998) · The Journal of Cell Biology · doi:10.1083/jcb.143.4.901 · Cited by 601
WORKMAN, P., BURROWS, F., NECKERS, L., & ROSEN, N. (2007) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1391.012 · Cited by 521
Eccles, S. A., Massey, A., Raynaud, F. I., Sharp, S. Y., Box, G., Valenti, M., Patterson, L., de Haven Brandon, A., Gowan, S., Boxall, F., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5256 · Cited by 479
Schulte, T. W., & Neckers, L. M. (1998) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800050817 · Cited by 478
CHIP: a link between the chaperone and proteasome systems
McDonough, H., & Patterson, C. (2003) · Cell Stress & Chaperones · doi:10.1379/1466-1268(2003)008<0303:calbtc>2.0.co;2 · Cited by 468
Brough, P. A., Aherne, W., Barril, X., Borgognoni, J., Boxall, K., Cansfield, J. E., Cheung, K.-M. J., Collins, I., Davies, N. G. M., Drysdale, M. J., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm701018h · Cited by 444
Exact Analysis of Competition Ligand Binding by Displacement Isothermal Titration Calorimetry
Sigurskjold, B. W. (2000) · Analytical Biochemistry · doi:10.1006/abio.1999.4402 · Cited by 368
Geldanamycin as a Potential Anti-Cancer Agent: Its Molecular Target and Biochemical Activity
Neckers, L., Schulte, T. W., & Mimnaugh, E. (1999) · Investigational New Drugs · doi:10.1023/a:1006382320697 · Cited by 301
50 Years of Preclinical Anticancer Drug Screening: Empirical to Target-Driven Approaches
Suggitt, M., & Bibby, M. C. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.971.11.3 · Cited by 298
Heat Shock Protein 90: Inhibitors in Clinical Trials
Biamonte, M. A., Van de Water, R., Arndt, J. W., Scannevin, R. H., Perret, D., & Lee, W.-C. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm9004708 · Cited by 285
Heat Shock Protein 90 as a Drug Target: Some Like It Hot
Banerji, U. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0132 · Cited by 244
Combinatorial attack on multistep oncogenesis by inhibiting the Hsp90 molecular chaperone
Workman, P. (2004) · Cancer Letters · doi:10.1016/j.canlet.2003.08.032 · Cited by 242
ErbB2 Degradation Mediated by the Co-chaperone Protein CHIP
Zhou, P., Fernandes, N., Dodge, I. L., Reddi, A. L., Rao, N., Safran, H., DiPetrillo, T. A., Wazer, D. E., Band, V., & Band, H. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m209640200 · Cited by 200
Pharmacokinetics in Drug Discovery
Ruiz-Garcia, A., Bermejo, M., Moss, A., & Casabo, V. G. (2008) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21009 · Cited by 199
Huang, K. H., Veal, J. M., Fadden, R. P., Rice, J. W., Eaves, J., Strachan, J.-P., Barabasz, A. F., Foley, B. E., Barta, T. E., Ma, W., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900230j · Cited by 192
Ge, J., Normant, E., Porter, J. R., Ali, J. A., Dembski, M. S., Gao, Y., Georges, A. T., Grenier, L., Pak, R. H., Patterson, J., et al. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm0603116 · Cited by 191
Blagg, B. S. J., & Kerr, T. D. (2006) · Medicinal Research Reviews · doi:10.1002/med.20052 · Cited by 189
Tumor models for efficacy determination
Teicher, B. A. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0391 · Cited by 186
Murray, C. W., Carr, M. G., Callaghan, O., Chessari, G., Congreve, M., Cowan, S., Coyle, J. E., Downham, R., Figueroa, E., Frederickson, M., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100059d · Cited by 184
Self-citationLundgren, K., Zhang, H., Brekken, J., Huser, N., Powell, R. E., Timple, N., Busch, D. J., Neely, L., Sensintaffar, J. L., Yang, Y.-C., et al. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0758 · Cited by 173
Brough, P. A., Barril, X., Borgognoni, J., Chene, P., Davies, N. G. M., Davis, B., Drysdale, M. J., Dymock, B., Eccles, S. A., Garcia-Echeverria, C., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900357y · Cited by 173
Squires, M. S., Feltell, R. E., Wallis, N. G., Lewis, E. J., Smith, D.-M., Cross, D. M., Lyons, J. F., & Thompson, N. T. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0890 · Cited by 171
Self-citationThe Metabolism and Pharmacokinetics of Amlodipine in Humans and Animals
Stopher, D. A., Beresford, A. P., Macrae, P. V., & Humphrey, M. J. (1988) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-198812007-00012 · Cited by 159
Lancet, J. E., Gojo, I., Burton, M., Quinn, M. F., Tighe, S., Kersey, K., Zhong, Z., Albitar, M. X., Bhalla, K. N., Hannah, A. L., et al. (2010) · Leukemia · doi:10.1038/leu.2009.292 · Cited by 156
Tumor Models for Efficacy Determination
Teicher, B. A. (2008) · AACR Education book · doi:10.1158/aacr.edb-mct-06-0391 · Cited by 154
AstexViewerTM †: a visualisation aid for structure-based drug design
Hartshorn, M. J. (2002) · Journal of Computer-Aided Molecular Design · doi:10.1023/a:1023813504011 · Cited by 145
Antiangiogenic Properties of 17-(Dimethylaminoethylamino)-17-Demethoxygeldanamycin
Kaur, G., Belotti, D., Burger, A. M., Fisher-Nielson, K., Borsotti, P., Riccardi, E., Thillainathan, J., Hollingshead, M. G., Sausville, E. A., & Giavazzi, R. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0795 · Cited by 145
Development of Radicicol Analogues
Soga, S., Shiotsu, Y., Akinaga, S., & Sharma, S. V. (2003) · Current Cancer Drug Targets · doi:10.2174/1568009033481859 · Cited by 143
Heat Shock Protein 90 Inhibitors. A Text Book Example of Medicinal Chemistry?
Janin, Y. L. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm050759r · Cited by 127
CUDC-305, a Novel Synthetic HSP90 Inhibitor with Unique Pharmacologic Properties for Cancer Therapy
Bao, R., Lai, C.-J., Qu, H., Wang, D.-G., Yin, L., Zifcak, B. M., Atoyan, R., Wang, J., Samson, M., Forrester, J. S., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0152 · Cited by 116
Death by chaperone: HSP90, HSP70 or both?
Powers, M. V., Clarke, P. A., & Workman, P. (2009) · Cell Cycle · doi:10.4161/cc.8.4.7583 · Cited by 99
Automated Protein–Ligand Crystallography for Structure‐Based Drug Design
Mooij, W. T. M., Hartshorn, M. J., Tickle, I. J., Sharff, A., Verdonk, M. L., & Jhoti, H. (2006) · ChemMedChem · doi:10.1002/cmdc.200600074 · Cited by 97
Wu, W., Burnett, D. A., Spring, R., Greenlee, W. J., Smith, M., Favreau, L. V., Fawzi, A. B., Zhang, H., & Lachowicz, J. E. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm030614p · Cited by 93
Madsen, P., Ling, A. L., Plewe, M. B., Sams, C. K., Knudsen, L. B., Sidelmann, U. G., Ynddal, L., Brand, C. L., Andersen, B., Murphy, D. E., et al. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm0208572 · Cited by 87
Brazidec, J. L., Kamal, A., Busch, D. J., Thao, L., Zhang, L., Timony, G. A., Grecko, R., Trent, K., Lough, R. E., Salazar, T., et al. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm0306125 · Cited by 84
hERG-related drug toxicity and models for predicting hERG liability and QT prolongation
Raschi, E., Ceccarini, L., Ponti, F. D., & Recanatini, M. (2009) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425250903055070 · Cited by 77
P-Glycoprotein–Mediated Resistance to Hsp90-Directed Therapy Is Eclipsed by the Heat Shock Response
McCollum, A. K., TenEyck, C. J., Stensgard, B. A., Morlan, B. W., Ballman, K. V., Jenkins, R. B., Toft, D. O., & Erlichman, C. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5175 · Cited by 77
Modelling prior distributions of atoms for macromolecular refinement and completion
Roversi, P., Blanc, E., Vonrhein, C., Evans, G., & Bricogne, G. (2000) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444900008490 · Cited by 62
Mechanistic Studies on Hsp90 Inhibition by Ansamycin Derivatives
Onuoha, S. C., Mukund, S. R., Coulstock, E. T., Sengerová, B., Shaw, J. S., McLaughlin, S. H., & Jackson, S. (2007) · Journal of Molecular Biology · doi:10.1016/j.jmb.2007.06.065 · Cited by 55
Structure‐Based and in silico Design of Hsp90 Inhibitors
Sgobba, M., & Rastelli, G. (2009) · ChemMedChem · doi:10.1002/cmdc.200900256 · Cited by 41
Medicinal Chemistry of Hsp90 Inhibitors
Drysdale, M., & Brough, P. A. (2008) · Current Topics in Medicinal Chemistry · doi:10.2174/156802608784911644 · Cited by 36
Prodromou, C., Piper, P. W., & Pearl, L. H. (1996) · Proteins Structure Function and Bioinformatics · doi:10.1002/(sici)1097-0134(199608)25:4<517::aid-prot13>3.0.co;2-k · Cited by 25
In Silico hERG Modeling: Challenges and Progress
Diller, D. (2009) · Current Computer - Aided Drug Design · doi:10.2174/157340909788451928 · Cited by 24
Cited by
Induced protein degradation: an emerging drug discovery paradigm
Lai, A. C., & Crews, C. M. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.211 · Cited by 1,486
The role of ligand efficiency metrics in drug discovery
Hopkins, A. L., Keserü, G. M., Leeson, P. D., Rees, D. C., & Reynolds, C. H. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4163 · Cited by 1,181
Self-citationHsp90 Molecular Chaperone Inhibitors: Are We There Yet?
Neckers, L., & Workman, P. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1000 · Cited by 891
Fragment-Based Approaches in Drug Discovery and Chemical Biology
Scott, D. E., Coyne, A. G., Hudson, S. A., & Abell, C. (2012) · Biochemistry · doi:10.1021/bi3005126 · Cited by 460
Targeting protein–protein interactions as an anticancer strategy
Ivanov, A. A., Khuri, F. R., & Fu, H. (2013) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2013.04.007 · Cited by 401
Metadata
- Authors
- Woodhead, A. J., Angove, H., Carr, M. G., Chessari, G., Congreve, M., Coyle, J. E., Cosme, J., Graham, B., Day, P. J., Downham, R., Fazal, L., Feltell, R., Figueroa, E., Frederickson, M., Lewis, J., McMenamin, R., Murray, C. W., O’Brien, M. A., Parra, L., Patel, S., Phillips, T., Rees, D. C., Rich, S., Smith, D.-M., Trewartha, G., Vinkovic, M., Williams, B., & Woolford, A. J.-A.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2010-07-28
- Volume
- 53
- Issue
- 16
- Pages
- 5956-5969
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2141715793
- Cited by
- 264
- References
- 58
- FWCI
- 7.92
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
